Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Citi lifts price target for Antofagasta after Centinela expansion

(Sharecast News) - Citi has raised its target price for Antofagasta and reiterated an 'buy' rating after the copper miner approved a $4.4bn expansion of its Centinela mine in Chile. The company announced in December that critical path works would begin immediately with full construction expected to commence after definitive project finance documents have been executed during the first quarter 2024. The expansion will add an average of 170,000 tonnes of copper equivalent production per annum.

"ANTO's growth narrative, driven by volume recovery in next 6-12 months, is solidified by the approval of Centinela expansion, adding another 170kt copper production over the medium term at an attractive cost profile," said Citi in a research note on Wednesday.

"The company is on track to increase its copper production 30% by 2027 while repositioning its portfolio lower on the global cost curve."

Meanwhile, Citi said its house view remains constructive on copper prices for medium to long term.

The bank has raised our target price for the shares to 2,100p, suggesting decent upside from Wednesday's price of 1,718.5p, up 0.7% on the day.

Share this article

Related Sharecast Articles

Biome Technologies shares sink as Q1 sales drop 44%
(Sharecast News) - Shares in AIM-listed Biome Technologies plummeted by almost a third on Monday after the bioplastics and radio frequency technology business reported a poor start to the year with first-quarter sales dropping by 44%.
Entain reprices two term loans, revises interest cost outlook
(Sharecast News) - Betting and gambling giant Entain announced the successful repricing of two of its existing 'Term Loan B' loans on Monday, along with the pricing and allocation of fungible add-ons, in a bid to optimise its financial position.
Oxford Biomedica confident as it moves away from vaccine era
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica reported stability in its core business on Monday, with a small increase in full-year core revenue for 2023, despite a 36% decrease in total revenue to £89.5m.
N Brown chairman Ron McMillan to retire
(Sharecast News) - N Brown said on Monday that chairman Ron McMillan will be retiring and stepping down from the board with effect from 30 April for personal reasons.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.